Diamond Hill Capital Management Inc. boosted its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 17.3% during the 4th quarter, Holdings Channel reports. The firm owned 3,158,638 shares of the company’s stock after buying an additional 465,839 shares during the quarter. Zoetis makes up about 2.0% of Diamond Hill Capital Management Inc.’s holdings, making the stock its 11th biggest position. Diamond Hill Capital Management Inc.’s holdings in Zoetis were worth $397,420,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB grew its holdings in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Montrusco Bolton Investments Inc. grew its holdings in Zoetis by 256.7% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock valued at $266,888,000 after buying an additional 1,560,314 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Zoetis by 83.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after acquiring an additional 1,227,085 shares during the last quarter. Finally, Corient Private Wealth LLC raised its holdings in shares of Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after acquiring an additional 1,191,840 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Insider Buying and Selling
In other news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.
Zoetis Price Performance
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.
Zoetis Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.
Wall Street Analyst Weigh In
A number of research firms have recently commented on ZTS. Citigroup lowered their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $134.75.
Check Out Our Latest Report on ZTS
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
